G1 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 100
- Market Cap
- $376.1M
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT03041311
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸Northside Hospital - Georgia Cancer Specialists, Atlanta, Georgia, United States
🇺🇦Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02983071
- Locations
- 🇧🇬
Special Hospital For Active Treatment In Oncology, Sofia, Bulgaria
🇧🇬MHAT for Womens Health - Nadezhda OOD, Sofia, Bulgaria
🇲🇩The Institute of Oncology, Chisinau, Moldova, Republic of
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02978716
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT02821624
- Locations
- 🇳🇱
PRA Early Development Clinic, Groningen, Netherlands
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT02514447
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02499770
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇫🇷CHU de Rennes Hopital Pontchaillou, Rennes, France
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02243150
- Locations
- 🇳🇱
PRA Early Development Clinic, Groningen, Netherlands